Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1885-1894

  Milani, Paolo ^a   Massacesi, Amedeo ^a   Ciaccia, Stefano ^a   Setaccioli, Marco ^a   Moschini, Stefania ^a   Bergamini, Fulvio ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Bevacizumab; Choroidal neovascularization; Macular degeneration; Optical coherence tomography; Pathologic myopia

Indexed keywords

BEVACIZUMAB;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; EYE REFRACTION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84869743363     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s34649     Document Type: Article

References (27)

1. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev. 2005;19:CD004765.
2. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal CNV in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology. 2003;110:667-673.
3. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010;30:407-412.
4. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina. 2008;28:1117-1123.
5. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009;29:750-756.
6. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247:311-318.
7. Lalloum F, Souied EH, Bastuji-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularisation complicating pathologic myopia. Retina. 2010;30:399-406.
8. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one year results. Am J Ophthalmol. 2009;147:94. e1-100. e1.
9. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol. 2007;17:620-626.
10. Hayashi K, Ohno-Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2009;247:609-618.
11. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157-160.
12. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye. 2009;23:2042-2045.
13. Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol. 2010;248:543-550.
14. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93:150-154.
15. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190-2196.
16. Ruiz-Moreno JM, Montero JA, Arias L, et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina. 2010;30:1609-1615.
17. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248:937-941.
18. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol. 2009;93:448-451.
19. Ng DS, Kwok AK, Chan CW. Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Experiment Ophthalmol. 2012;40(1):e98-e110.
20. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol. 2009;148:396-408.
21. Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol. 2010;149:140-146.
22. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol. 2010;94:864-870.
23. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009;147:84-93. e1.
24. Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naïve myopic choroidal neovascularization. Retina. 2012;32(5):949-955.
25. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina. 2011;31:1841-1847.
26. Milani P, Pece A, Moretti G, Lino P, Scialdone A. Intravitreal bevacizumab for CNV-complicated tilted disk syndrome. Graefes Arch Clin Exp Ophthalmol. 2009;247:1179-1182.
27. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol. 2010;149:458. e1-464. e1.